NCT05907954Phase 2Active not recruiting

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Study sponsor: IDEAYA Biosciences

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-04-30Estimated
Enrollment · participants160Estimated
Source updated2026-03-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview